Mirae Asset Global ETFs Holdings
CHRS icon

Mirae Asset Global ETFs Holdings’s Coherus Oncology CHRS Stock Holding History

Mirae Asset Global ETFs Holdings’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$85.3K Buy
50,445
+1,170
+2% +$2.08K ﹤0.01% 2736
2025
Q4 		$70K Sell
49,275
-5
-0% -$7 ﹤0.01% 2829
2025
Q3 		$80.8K Sell
49,280
-14,581
-23% -$16.2K ﹤0.01% 2760
2025
Q2 		$46.7K Sell
63,861
-2,852
-4% -$2.46K ﹤0.01% 2894
2025
Q1 		$53.8K Buy
66,713
+2,839
+4% +$3.27K ﹤0.01% 2837
2024
Q4 		$88.1K Buy
63,874
+4,171
+7% +$4.68K ﹤0.01% 2747
2024
Q3 		$62.1K Buy
59,703
+6,012
+11% +$8.24K ﹤0.01% 2874
2024
Q2 		$92.9K Buy
+53,691
New +$108K ﹤0.01% 2593

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Mirae Asset Global ETFs Holdings's CHRS Position: Q1 2026 in Review

Mirae Asset Global ETFs Holdings increased its Coherus Oncology (CHRS) stake by 2.4% in Q1 2026, buying an estimated $2.08K and bringing the position to 50,445 shares worth $85.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2736.

Mirae Asset Global ETFs Holdings first reported a position in CHRS in Q2 2024 and has held it in 8 quarters since. The position peaked at $92.9K in Q2 2024. 157 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Mirae Asset Global ETFs Holdings held 50,445 shares of Coherus Oncology worth $85.3K as of Q1 2026.
  • Mirae Asset Global ETFs Holdings bought 1,170 Coherus Oncology shares in Q1 2026, an estimated $2.08K.
  • Coherus Oncology made up ﹤0.01% of Mirae Asset Global ETFs Holdings's portfolio in Q1 2026, its #2736 holding.
  • Mirae Asset Global ETFs Holdings first reported a position in Coherus Oncology in Q2 2024 and has held it in 8 quarters since.
  • Mirae Asset Global ETFs Holdings's Coherus Oncology position peaked at $92.9K in Q2 2024.
  • 157 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Mirae Asset Global ETFs Holdings's 13F filing for Q1 2026, filed 15 May 2026.